Eli Lilly Downgrade Highlights Intensifying Price Competition, Aligns with DeepValue's Risk Assessment

What happened

HSBC has downgraded Eli Lilly stock, citing stiff price competition for its key drugs Zepbound and Mounjaro in the coming year. This news directly echoes the DeepValue master report's caution that Lilly faces significant pricing headwinds as the GLP-1 market transitions from supply scarcity to a price-and-access phase. The report specifically warns of Novo Nordisk's $675 WAC anchor for 2027 and policy actions flagged in filings that could compress net prices, threatening earnings durability. Despite Lilly's Q4-2025 volume growth of 46%, it already absorbed a 5% price decline, and its high valuation at 42.9x trailing P/E offers minimal margin for error. The downgrade underscores the need for investors to closely monitor gross-to-net trends and FDA updates on oral GLP-1 orforglipron, as highlighted in the report's WAIT rating.

Implication

First, the HSBC downgrade validates the DeepValue report's view that Lilly's valuation is exposed to accelerating price competition, increasing the likelihood of the bear case where net price compression outpaces volume growth. Second, investors must scrutinize upcoming quarterly results for signs of price declines exceeding the current 5% headwind, which could trigger multiple compression given the high P/E ratio. Third, the oral GLP-1 orforglipron remains a critical catalyst but faces timing uncertainty and competitive pressure from Novo's approved pill, requiring clear FDA milestones to support the bull case. Fourth, policy-driven reimbursement changes and payer negotiations in 2026 will be pivotal in determining net pricing stability, as flagged in Lilly's filings. Fifth, with the narrative crowded and valuation elevated, positioning should align with the report's recommendation to wait for entry near $900 or evidence of pricing resilience.

Thesis delta

The HSBC downgrade does not shift the core thesis but confirms and slightly intensifies the downside risks outlined in the DeepValue report. It increases the emphasis on monitoring price compression as a near-term threat, though the overall WAIT rating and need for operational proof points remain unchanged.